New study shows investors optimistic for US Biotech's future

A new study released by the USA’s Biotechnology Industry Organization (BIO) Industry Analysis and Ipreo shows that investors are optimistic on biotech’s future and investment in biotechnology will continue to perform well.

“This survey illustrates the long-term confidence that investors have in our industry while detailing the various challenges that impact valuation,” said Alan Eisenberg, executive vice president of emerging companies and business development at BIO, noting that “the data will provide considerable insight into current investor perceptions of the industry that may be helpful in anticipating the sector’s performance this year.”

The study gathered feedback from 135 investment professionals representing firms with $2 trillion in equity assets under management, including $166 billion invested in healthcare and $38 billion invested in biotech.